Antibodies specific for TGF-beta and methods for treating thereof
AssigneeXoma Technology Ltd.
InventorsDaniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.
Claims21
An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising:
- (a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO:
- 19, or a variant thereof in which one or two amino acids have been changed;
- (b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO:
- 20, or a variant thereof in which one or two amino acids have been changed;
- (c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO:
- 21, or a variant thereof in which one or two amino acids have been changed;
- (d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO:
- 22, or a variant thereof in which one or two amino acids have been changed;
- (e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO:
- 23, or a variant thereof in which one or two amino acids have been changed;
- and
- (f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO:
- 24, or a variant thereof in which one or two amino acids have been changed.
An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising a light chain variable region and a heavy chain variable region, wherein
- (a) the light chain variable region comprises at least a CDR1 amino acid sequence set out in SEQ ID NO:
- 22, a CDR2 amino acid sequence set out in SEQ ID NO:
- 23, and a CDR3 amino acid sequence set out in SEQ ID NO:
- 24;
- and wherein
- (b) the heavy chain variable region comprises at least a CDR1 amino acid sequence set out in SEQ ID NO:
- 19, a CDR2 amino acid sequence set out in SEQ ID NO:
- 20, and a CDR3 amino acid sequence set out in SEQ ID NO:
- 21.
Dependencies are inferred from the claim text.